Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes: Results from the Diabetes Atherosclerosis Intervention Study (DAIS)-Reference-Cited by-同舟云学术

Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes: Results from the Diabetes Atherosclerosis Intervention Study (DAIS)

Published:2005-03 Issue:3 Volume:45 Page:485-493
ISSN:0272-6386
Container-title:American Journal of Kidney Diseases
language:en
Short-container-title:American Journal of Kidney Diseases

Author:

Ansquer Jean-Claude,Foucher Christelle,Rattier Stephanie,Taskinen Marja-Riitta,Steiner George

Publisher

Elsevier BV

Subject

Nephrology

Reference21 articles.

1. Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes;Mogensen;N Engl J Med,1984

2. Microalbuminuria in type 2 diabetes;Beilin;Aust N Z J Med,1996

3. The importance of microalbuminuria as a cardiovascular risk indicator;Diercks;Can J Cardiol,2002

4. Treatment of the participant with diabetes mellitus and risk of nephropathy;Hollenberg;Arch Intern Med,2004

5. Lipid nephrotoxicity in chronic progressive glomerular and tubulo-interstitial disease;Moorehead;Lancet,1982

Cited by 220 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. (-)-Gallocatechin Gallate Mitigates Metabolic Syndrome-Associated Diabetic Nephropathy in db/db Mice;Foods;2024-06-03

2. Switching from Conventional Fibrates to Pemafibrate Has Beneficial Effects on the Renal Function of Diabetic Subjects with Chronic Kidney Disease;Diabetes & Metabolism Journal;2024-05-31

3. Not enough known about fenofibrate’s kidney effects in people with Type 2 diabetes;Diabetes Research and Clinical Practice;2024-04

4. Fenofibrate Attenuates Renal Tubular Cell Apoptosis by Up-Regulating MCAD in Diabetic Kidney Disease;Drug Design, Development and Therapy;2023-05

5. The Association of Background Medications on Initial eGFR Change and Kidney Outcomes in Diabetic Patients Receiving SGLT2 Inhibitor;Clinical Journal of the American Society of Nephrology;2023-03-31